Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,191
archived clinical trials in
Constipation

Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Inquest Center, Ltd.
mi
from
Dayton, OH
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Inquest Center, Ltd.
mi
from
Dayton, OH
Click here to add this to my saved trials
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated:  7/7/2015
NPC Research
mi
from
Oklahoma City, OK
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated: 7/7/2015
NPC Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated:  7/7/2015
Pain Research of Charleston
mi
from
Charleston, SC
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated: 7/7/2015
Pain Research of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated:  7/7/2015
Family Medicine of SayeBrook, LLC
mi
from
Myrtle Beach, SC
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated: 7/7/2015
Family Medicine of SayeBrook, LLC
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated:  7/7/2015
Highland Clinical Research
mi
from
Salt Lake City, UT
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated: 7/7/2015
Highland Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated:  7/7/2015
University of Calgary
mi
from
Calgary,
Longitudinal Study of Patients With Opioid-Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
Status: Enrolling
Updated: 7/7/2015
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Anniston, AL
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Anaheim, CA
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
DeLand, FL
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Hollywood, FL
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Orlando, FL
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
South Miami, FL
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Overland Park, KA
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Marlton, NJ
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Raleigh, NC
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  7/7/2015
Clinical Research Facility
mi
from
West Bend, WI
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 7/7/2015
Clinical Research Facility
mi
from
West Bend, WI
Click here to add this to my saved trials
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome
Status: Enrolling
Updated:  7/17/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome
Status: Enrolling
Updated: 7/17/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome
Status: Enrolling
Updated:  7/17/2015
Georgia Health Sciences University
mi
from
Augusta, GA
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome
Status: Enrolling
Updated: 7/17/2015
Georgia Health Sciences University
mi
from
Augusta, GA
Click here to add this to my saved trials
Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients
A Prospective, Randomized Trial of Enteral Naloxone Versus a Traditional Bowel Regimen in Prevention of Constipation and Decreased Gastric Motility in Critically Ill Trauma Patients
Status: Enrolling
Updated:  7/27/2015
Charleston Area Medical Center, General Hospital
mi
from
Charleston, WV
Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients
A Prospective, Randomized Trial of Enteral Naloxone Versus a Traditional Bowel Regimen in Prevention of Constipation and Decreased Gastric Motility in Critically Ill Trauma Patients
Status: Enrolling
Updated: 7/27/2015
Charleston Area Medical Center, General Hospital
mi
from
Charleston, WV
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
Wayne State University
mi
from
Detroit, MI
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
Brown University
mi
from
Providence, RI
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
Brown University
mi
from
Providence, RI
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
Vanderbilt University
mi
from
Nashville, TN
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
University of Vermont
mi
from
Burlington, VT
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated:  7/30/2015
Medical University of Vienna
mi
from
Vienna,
RCT Comparing Methadone and Buprenorphine in Pregnant Women
Maternal Opioid Treatment: Human Experimental Research
Status: Enrolling
Updated: 7/30/2015
Medical University of Vienna
mi
from
Vienna,
Click here to add this to my saved trials
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects
Status: Enrolling
Updated:  8/5/2015
Vince and Associates Clinical Research
mi
from
Overland Park, KA
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects
Status: Enrolling
Updated: 8/5/2015
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Birmingham, AL
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Calera, AL
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Calera, AL
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Muscle Shoals, AL
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Tallassee, AL
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Tallassee, AL
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Glendale, AZ
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Phoenix, AZ
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Sun City, AZ
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Sun City, AZ
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Tucson, AZ
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Hot Springs, AR
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Little Rock, AR
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Anaheim, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Beuna Park, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Beuna Park, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Burbank, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Burbank, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Duarte, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Duarte, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Fountain Valley, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Huntington Beach, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Mission Viejo, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Orange, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Redlands, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Redlands, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
San Diego, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Vista, CA
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Vista, CA
Click here to add this to my saved trials
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Waterbury, CT
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Waterbury, CT
Click here to add this to my saved trials